leadf
logo-loader
viewSkinBioTherapeutics PLC

SkinBioTherapeutics' Cath O'Neill 'thrilled' with human study data for skin cream

Dr Cath O’Neill, chief executive of SkinBioTherapeutics PLC (LON:SBTX), speaks to Proactive's Andrew Scott after announcing the results from the company’s first human study of its SkinBiotix cream.

The data has shown the product to be well tolerated and efficacious in certain age groups and at certain time points.

Quick facts: SkinBioTherapeutics PLC

Price: 19.5 GBX

AIM:SBTX
Market: AIM
Market Cap: £24.98 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of SkinBioTherapeutics PLC named herein, including the promotion by the Company of SkinBioTherapeutics PLC in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

SkinBioTherapeutics CEO hails 'significant scientific milestone' with...

SkinBioTherapeutics PLC's (LON:SBTX) CEO Stuart Ashman speaks to Proactive's Andrew Scott soon after updating investors on the progress of its cosmetic skincare programme and plans for a psoriasis food supplement trial. Sederma, its partner in the cosmetics programme and a division of Croda...

on 3/8/20

2 min read